Clik here to view.
The Renaissance man: how to become a scientist over and over again
Editor’s note: This post originally ran on Ed Yong’s blog, Not Exactly Rocket Science, and has been reposted here with permission. -B.Mossop ** Erez Lieberman Aiden is a talkative witty fellow, who...
View ArticleClik here to view.
Should Chimpanzees Have Moral Standing? An Interview with Frans de Waal
Frans de Waal (Photo: Catherine Marin) Whether from hubris or insecurity, humans like to view our species as the crown of creation, beings beyond compare in the animal kingdom, as if our advanced...
View ArticleClik here to view.
Fish, Antidepressants, Autism and a Problematic Research Premise
This week saw publication of a PLOS One paper on a potential environmental cause of autism that caught the attention of the media. The Daily Mail, a newspaper that has a track record of sensationalist...
View ArticleClik here to view.
Tim Vollmer of Creative Commons on HowOpenIsIt?
This is a guest post from Timothy Vollmer, Manager of Policy and Data for Creative Commons Congratulations to PLOS, SPARC, and OASPA for taking a productive, positive approach to explaining various...
View ArticleCitizenship, Scholarship, and the Republic of Science
A guest post for OA Week by Barbara Fister Every spring, when I teach a course for upper-division undergraduates interested in knowing more about how information works before they go on to grad school,...
View ArticleClik here to view.
Reusing, Revising, Remixing and Redistributing Research
An OA Week guest post by Daniel Mietchen The initial purpose of Open Access is to enable researchers to make use of information already known to science as part of the published literature. One way to...
View ArticleClik here to view.
Open Access From a Patient Advocate’s Perspective: “Inserting Ourselves into...
An OA Week guest post by patient advocate Christy Collins My daughter, Signe, was born with a very rare genetic condition called macrocephaly-capillary malformation syndrome or M-CM. This syndrome...
View ArticleClik here to view.
Why Science Journal Paywalls Have to Go
A guest post by student scientist Jack Andraka After a close family friend died from pancreatic cancer, I turned to the Internet to help me understand more about this disease that had killed him so...
View ArticleClik here to view.
A Story of 20,000 Healthy Mothers and Babies by Dr. Nosakhare Orobaton
[Originally published as a PLOS BLOGS Network guest post on December 10, 2013] By Dr. Nosakhare Orobaton Image Credit: Original image by Jack Zalium, flickr. Alterations by Richard Basset, PLOS. To...
View ArticleClik here to view.
NeuroTribes: Steve Silberman on a haunting history and new hope for autistic...
To mark the publication of the book NeuroTribes (Aug 25, 2015; Avery/Penguin Random House) by Steve Silberman, whose blog of the same name has been hosted on the PLOS BLOGS Network since 2010, we...
View ArticleClik here to view.
Talking about Drug Prices & Access to Medicines Pt 1: By Els Torreele, Open...
Welcome to a PLOS BLOGS six-part series, Talking about Drug Prices & Access to Medicines. To borrow a phrase from one of our bloggers, “Rage and public outcries are not a rational way to manage...
View ArticleClik here to view.
Talking Drug Prices Pt 2: This Blog Post Will Cost You by Jessica Wapner
Welcome to the second in a PLOS BLOGS six-part series, Talking about Drug Prices & Access to Medicines. To borrow a phrase from one of our bloggers, “Rage and public outcries are not a rational way...
View ArticleClik here to view.
Talking Drug Prices, Pt. 3 If you play with scorpions, don’t be surprised...
Welcome to the third in a PLOS BLOGS six-part series, Talking about Drug Prices & Access to Medicines. To borrow a phrase from one of our bloggers, “Rage and public outcries are not a rational way...
View ArticleClik here to view.
Talking Drug Prices, Pt 4 Drug pricing is out of control, what should be...
Welcome to part four in a PLOS BLOGS six-part series, Talking about Drug Prices & Access to Medicines. To borrow a phrase from one of our bloggers, “Rage and public outcries are not a rational way...
View ArticleClik here to view.
Talking About Drug Prices, Pt 5: Double-billed… By Manica Balasegaram, MSF
Welcome to part five in a PLOS BLOGS six-part series, Talking about Drug Prices & Access to Medicines. To borrow a phrase from one of our bloggers, “Rage and public outcries are not a rational way...
View ArticleClik here to view.
Talking drug prices, Pt 6: Openness vs. secrecy in drug development By Mat Todd
Welcome to the sixth and final post in a PLOS BLOGS series, Talking about Drug Prices & Access to Medicines. To borrow a phrase from one of our bloggers, “Rage and public outcries are not a...
View ArticleClik here to view.
Known Knowns and Unknowns of U.S. Drug Pricing
By Joshua P. Cohen Research Associate Professor, Tufts Center for the Study of Drug Development (Full bio below this post) Media scrutiny of high drug costs In the U.S. spending on drugs represents...
View ArticleClik here to view.
The U.S. Needs a Lesson in Food Policy from Mexico by Daniel Taber, PhD, MPH
What do you tell people when you’re an invited “expert,” yet in some ways you’re the dumbest person in the room? That was my thought in February 2014, when Mexican leaders invited me to speak at a...
View ArticleClik here to view.
Ending a Global Epidemic: Tuberculosis in Children #UnitetoEndTB
“When my daughter got sick, I took her to a clinic in my neighborhood. They gave her cough syrup for seven days. I thought she was getting better, but it was apparent that she was still ill. After...
View ArticleClik here to view.
Researcher ‘First Person’: Why Context Matters When Assessing Autistic Traits
0000-0002-8715-2896PLOSBLOGS Editor’s Note: From time to time we feature “first person” blog posts by PLOS journal authors, particularly when their newly published findings provide insights of interest...
View Article